West Pharmaceutical Services, Inc. (WST) Earnings
West Pharmaceutical Services, Inc. is expected to report next earnings on October 22, 2026 (in NaN days), with a consensus EPS estimate of $2.17. WST has beaten EPS estimates in 11 of its last 12 reported quarters (average surprise +17.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 23, 2026 | $2.08 | $2.37 | +13.9% | $872M | +3.8% |
| Apr 23, 2026 | $1.68 | $2.13 | +26.8% | $845M | +8.3% |
| Feb 12, 2026 | $1.83 | $2.04 | +11.5% | $805M | +4.1% |
| Oct 23, 2025 | $1.68 | $1.96 | +16.7% | $804M | +2.4% |
| Jul 24, 2025 | $1.51 | $1.84 | +21.9% | $766M | +5.5% |
| Apr 24, 2025 | $1.22 | $1.45 | +18.9% | $698M | -2.1% |
| Feb 13, 2025 | $1.71 | $1.82 | +6.4% | $749M | +1.1% |
| Oct 24, 2024 | $1.50 | $1.85 | +23.3% | $747M | +5.3% |
| Jul 25, 2024 | $1.74 | $1.52 | -12.6% | $702M | -3.8% |
| Apr 25, 2024 | $1.26 | $1.56 | +23.8% | $695M | +3.7% |
| Feb 15, 2024 | $1.78 | $1.83 | +2.8% | $732M | -1.0% |
| Oct 26, 2023 | $1.86 | $2.16 | +16.1% | $747M | -0.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Core Strategic Growth Drivers - **Biologics & Biosimilars**: Approximately 75% of 2025 new drug approvals are large biologic molecules, and West holds a >90% win rate for new biologic molecules. Biologics require high-quality barrier film components, driving strong growth for West's premium Floratec and Novapyr products. Easing regulations and a wave of upcoming patent expirations for biologics are driving rapid biosimilars market expansion, which generally maintains or increases West's component volume demand after commercial launch. - **HVP Upgrades (Annex 1)**: This is a multi-year early-stage opportunity, with total in-hand projects up 50% year-over-year to nearly 800. Customer upgrades to HVP components (often adding value-added finishing like InVision inspection) drive positive mix shift that improves both revenue and margins. Management expects this mix shift to deliver 200 bps of revenue growth in 2026, with upside potential as adoption expands beyond Europe to the U.S. - **GLP-1 Therapies**: Global GLP-1 adoption remains in early stages, with Medicare expansion in the U.S. driving further market growth. Injectable GLP-1s maintain clear efficacy and safety advantages over oral alternatives, and oral GLP-1s are expanding the overall market rather than cannibalizing injectable demand. West is well positioned to benefit from generic GLP-1 launches (which typically reuse existing high-value component designs) and the growing pipeline of next-generation GLP-1 molecules for new indications. ### Operational Updates - West completed the planned sale and transfer of manufacturing and supply rights for the SmartDOS 3.5 mL on-body delivery system on July 1, 2026. - The company fully recovered from the Q2 cyber incident, with strong underlying performance exceeding management expectations. The cyber incident delayed WestVantage revenues, which are expected to be recovered in the second half of 2026. - West renewed its 50+ year strategic partnership with Daikyo. - All three geographic regions delivered double-digit organic growth in Q2 2026, with Asia Pacific leading at 27% organic growth driven by generic GLP-1 biosimilar activity in China, India, and South Korea, plus growing CDMO support for innovative biologics. - Key manufacturing sites: Eschweiler (largest global HVP components site) delivered double-digit productivity and throughput improvement in H1 2026 that enabled faster cyber incident recovery; Grand Rapids (WestVantage) is nearly fully ramped to 2026 expected throughput; Dublin is still in ramp-up for new drug handling business, with revenue growth back-loaded to Q4 2026. ### Financial Highlights - Total company gross margin reached 37.7% in Q2 2026, up 200 bps year-over-year, driven by positive mix shift to HVP components and price contributions. Adjusted operating margin reached 22.6%, up 230 bps year-over-year. - Adjusted diluted EPS was $2.37 in Q2 2026, up 29% year-over-year and 28 cents above the prior guidance midpoint. - Capital expenditure guidance for full year 2026 remains $250 million to $275 million. West repurchased $157 million of shares in Q2 2026 as part of its $1 billion share repurchase program, maintaining a strong balance sheet for growth and shareholder returns.
Guidance
- **Full year 2026 organic revenue growth guidance**: Raised to 10% to 11%, up from the prior 7% to 9% range. Total reported revenue is now guided to $3.345 billion to $3.38 billion, an increase of $40 billion at the midpoint even after absorbing incremental FX headwind from a stronger U.S. dollar. - **Full year 2026 adjusted EPS guidance**: Raised to $8.85 to $9.05, representing 21% to 24% year-over-year growth. The guidance incorporates 200+ bps of full year operating margin expansion compared to 2025, unchanged from prior margin expectations despite rising oil and commodity inflation, which management expects to offset through internal initiatives. - **HVP components full year 2026 guidance**: Both GLP-1 and non-GLP-1 HVP components are now expected to deliver high teens organic growth, an upward revision from prior expectations. - **HVP delivery devices full year 2026 guidance**: Growth expectations were raised, while guidance for standard products and WestVantage remained broadly consistent with prior forecasts. - **Q3 2026 guidance**: Revenue is expected to be $820 million to $835 million, representing 7% to 8.9% organic growth. Q3 adjusted diluted EPS is expected to be $2.14 to $2.24, up 9% to 14% year-over-year. Q3 is expected to be the revenue trough for WestVantage following the exit of the CGM contract, with performance expected to improve in Q4 2026 as new drug handling business ramps.
Segment performance
1. Proprietary Products: Organic growth of 15.5% year-over-year. This segment includes three sub-segments: - HVP Components: Generated $424 million in Q2 2026, accounting for 49% of total company revenue (up from 46% in the prior year quarter. It delivered 18.4% organic year-over-year growth, with both GLP-1 and non-GLP-1 HVP components growing high teens organically. - HVP Delivery Devices: Generated $131 million in Q2 2026, delivering 29% organic year-over-year growth. Excluding the divested SmartDOS 3.5 business, the remaining portion of the segment (which accounts for more than half of HVP delivery device revenue) grew double digits, led by SelfDose and Crystal Xena. - Standard Products: Generated $167 million in Q2 2026, accounting for 19% of total company revenue, delivering 0.7% organic year-over-year growth. 2. WestVantage (West's Advantage): Generated $150 million in Q2 2026, accounting for 17% of total company revenue, delivering 0.8% organic year-over-year growth. Growth was impacted by a mid single-digit headwind from the earlier Q2 cyber incident, with delayed revenues expected to shift to the second half of 2026. Total company Q2 2026 revenue was $872 million, with 12.7% organic growth and 13.8% reported year-over-year growth.
Risks & headwinds
- The company experienced a cyber incident in early Q2 2026 that negatively impacted WestVantage segment revenue in the quarter, though all delayed revenues are expected to be recovered in the second half of 2026. - Persistent inflationary pressure from rising oil and commodity prices represents a headwind to margins, though management expects to fully offset these costs through internal initiatives and price adjustments. - Foreign exchange headwinds have increased since the prior earnings call due to a stronger U.S. dollar, which reduced the full year 2026 revenue guidance midpoint even after the upward revision from strong underlying performance.
Analyst Q&A
Q: What is driving the stronger-than-expected performance of non-GLP-1 HVP components, and how sustainable is this strength? /
A: Management cites three core sustainable drivers: first, strong growth from biologics and biosimilars, with a >90% win rate on new molecules, expanding uptake of existing molecules, and growing biosimilar adoption. Second, rapidly growing Annex 1-related HVP upgrade projects, which are up 50% year-over-year to nearly 800 projects, with expansion beyond Europe to the U.S. This is a multi-year early-stage opportunity with significant long-term runway. Third, operational excellence improvements that enabled faster recovery from the Q2 cyber incident. Management notes that as the incumbent supplier, it is well positioned to capture this growth long-term.
Q: After the strong Q2 beat, is the raised full year guidance still intentionally conservative, and what moving pieces should investors watch in the second half? /
A: Management confirms it maintains a prudent forecasting approach but says there is clear strong underlying momentum in the high-margin HVP components business that drives both top-line and profit growth. The only major moving pieces are the already-disclosed cyber incident revenue delay (expected to be recovered in H2) and the SmartDOS 3.5 divestiture, with no additional unpriced headwinds. Management says it is well positioned to deliver strong H2 performance.
Q: After the SmartDOS 3.5 divestiture, what is the long-term growth outlook for West's remaining delivery device portfolio? /
A: Management says the remaining portfolio has attractive margins after removing the dilutive SmartDOS 3.5 business. SelfDose is seeing healthy expansion across multiple customers and drug molecules. Crystal Xena is targeted at high-value cell and gene therapy products, representing a clear growing opportunity. Existing administration systems deliver mid-single to high-single-digit growth, leveraging West's core injection molding and design competencies. The entire remaining portfolio is growing double digits, and management expects this momentum to continue.
Q: What is the order of magnitude of mix shift growth from different HVP component product lines? /
A: Biologics are the strongest growth driver, and they utilize West's highest-ASP, highest-margin premium products (Novapeer, Floratec). This trend will become more pronounced as more biologic molecules launch and gain volume, with biosimilars typically retaining the incumbent premium component configuration, maintaining attractive economics. Annex 1 upgrades are the second key driver, adding value by upgrading existing formulations with premium finishing (like pharmaceutical washing and InVision inspection), which is margin accretive and leverages existing manufacturing assets. Annex 1 is also seeing multi-step upgrading: even existing HVP products are being upgraded to higher-value offerings, expanding the total opportunity, with potential upside to the current 200 bps annual growth contribution target.